<DOC>
	<DOCNO>NCT00638716</DOCNO>
	<brief_summary>This multicenter , randomize , placebo-controlled , double-blind , Phase II study . The objective study evaluate efficacy safety 12 week treatment CJC-1134-PC patient type 2 diabetes mellitus currently metformin monotherapy .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety CJC-1134-PC Patients With Type 2 Diabetes Mellitus Who Are Currently Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Major BMI : 27 45 kg/m2 Stable Type 2 diabetes mellitus least 3 month , define Investigator Stable lifestyle , i.e . diet &amp; physical activity , determine Investigator Stable metformin daily dose ≥1000 mg least 3 month Glycosylated hemoglobin ( HbA1c ) screen ≥ 7.1 % ≤ 11 %</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Type 2 Diabetes Mellitus , incretins , GLP-1 , HbA1c , metformin</keyword>
</DOC>